Lo William Wing Yan Dr reported disposition to issuer involving 70,600 derivative units of Regencell Bioscience Holdings Ltd on May 27, 2026

Disposition to issuer
Form 4 code D. Disposition of issuer equity securities to the issuer under Rule 16b-3(e).
Director
DIR
Filed May 29, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
—Shares × reported price
Shares traded
70,600Stock option (right to purchase)
Price per share
Price unknownReported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
521,630Direct
Trade date
May 27, 2026Disposition to issuer
Filed
May 29, 2026, 6:20 AM ET2-day reporting delay
Accession
0001213900-26-062409Code D · Transaction 95272
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

RGC price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
RGC · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +22%1w ago +15%1d ago +1.7%
Returns since7d −16%30d −73%90d180d1y

Footnotes in full

F1: The exercise price has given effect to the share split(s) of the Issuer since the date of grant of the option. F2: On May 27, 2026, the Issuer repurchased from the Reporting Person options to purchase 70,600 ordinary shares of the Issuer at a price of $15.00 per option. The aggregate consideration payable to the Reporting Person under the Option Repurchase Agreement is further reduced by the aggregate exercise price of the repurchased options.